The US Food and Drug Administration (FDA) has approved anti-PD-1 monoclonal antibodies (mAbs) nivolumab and pembrolizumab as second-line therapies for advanced HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.